Alectinib

Drug Profile

Alectinib

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche; University College London
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 19 Jun 2017 Adverse events and efficacy data from the phase III ALEX trial in Non small cell lung cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 13 Jun 2017 Roche plans a phase II/III trial for Non-small cell lung cancer(Monotherapy, Combination therapy, Inoperable/unresectable, Metastatic disease, Late-stage disease) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand (NCT03178552)
  • 05 Jun 2017 Adverse events data from the phase III ALEX trial in Non small cell lung cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top